Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Cash from Investing Activities data on record, last reported at -$15.3 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 681.94% year-over-year to -$15.3 million; the TTM value through Dec 2025 reached -$13.5 million, down 483.06%, while the annual FY2025 figure was -$13.5 million, 483.06% down from the prior year.
  • Cash from Investing Activities reached -$15.3 million in Q4 2025 per LCTX's latest filing, down from -$12000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $19.2 million in Q2 2023 and bottomed at -$40.9 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$317705.9, with a median of -$12000.0 recorded in 2025.
  • Peak YoY movement for Cash from Investing Activities: surged 33634.78% in 2023, then tumbled 681.94% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at $10.1 million in 2021, then tumbled by 150.65% to -$5.1 million in 2022, then surged by 290.94% to $9.7 million in 2023, then tumbled by 72.95% to $2.6 million in 2024, then crashed by 681.94% to -$15.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$15.3 million in Q4 2025, -$12000.0 in Q3 2025, and -$14000.0 in Q2 2025.